金斯瑞生物科技（01548.HK）今日盘中大跌5.19%，引发市场关注。尽管公司最新公布的中期业绩显示亏损大幅收窄，但似乎未能提振投资者信心。
根据公司公告，金斯瑞生物科技截至2025年6月30日止六个月的未经审核合并中期业绩显示，持续经营业务收益达5.19亿美元，同比增长81.92%。母公司拥有人应占亏损收窄至2546.2万美元，较去年同期的1.75亿美元亏损大幅改善，同比收窄85.46%。每股基本亏损为1.18美分。
尽管业绩有所改善，但投资者似乎对公司的盈利前景仍持谨慎态度。市场分析人士指出，虽然亏损收窄是积极信号，但公司仍未能实现盈利，这可能是导致股价下跌的原因之一。此外，全球经济不确定性增加，也可能影响投资者对生物科技股的风险偏好。投资者可能需要看到公司在未来几个季度的持续改善，才能重建信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.